European Reference Networks: Share, Care, and Cure—Future or Dream?

Abstract

European Reference Networks (ERNs) are virtual networks that involve healthcare providers across Europe. The aim of ERNs is to tackle complex or rare diseases and conditions that necessitate highly specialized treatment, knowledge and resources.

This article summarizes the concept of European Reference Networks in the European Union, legislation and policy behind ERNs from the standpoint of pediatric surgical specialty. There are seven ERNs in which pediatric surgeons are involved, four of which are being discussed, namely ERN PaedCan, eUROGEN ERN, ERN RARE-LIVER and ERNICA. ERNs program is a step towards improving health care quality, reducing access inequalities, and increasing overall medical experience and knowledge but its final impact is yet to be determined.

Keywords

rare diseases - children - networking

• References

• 1 Official Journal of the European Union. Consolidated versions of the Treaty on European Union and the Treaty on the Functioning of the European Union. Off J Eur Union 2012; 0001-0390
• 2 Commission of the European Communities. Communication from the Commission to the European Parliament, The Council, The European Economic and Social Committee and the Committee of the regions on Rare Diseases: Europe's challenges. Off J Eur Union 2008; 679
• 3 Council of the European Union. Directive 2011/24/EU. Off. J. Eur. Union [Internet]. 2011 ; 45–65. Available at: http://data.europa.eu/eli/dir/2011/24/oj . Accessed July 31, 2017
• 4 The European Parliament and of the Council. Commission Delegated Decision 2014/286/EU. I. 2014
• 5 European Parliament, Council of the European Union. Commission Implementing Decision (EU) No 2014/132. Off J Eur Union 2014; ; OJ L 71; 20-23
• 6 European Commission. Public Health. https://ec.europa.eu/health/ern/implementation/call_en
• 7 European Commission Directorate-General for Health and Food Safety. Rare Disease European Reference Networks: Addendum to Eucerd recommendations of January 2013: The decision of the Commission expert group on rare diseases. Off J Eur Union 2013/c 219/04: 4-7
• 8 Taruscio D, Gentile AE, Evangelista T, Frazzica RG, Bushby K, Montserrat AM. Centres of Expertise and European Reference Networks: key issues in the field of rare diseases. The EUCERD Recommendations. Blood Transfus 2014; 12 (Suppl. 03) 621-625
• 9 Wilson C. Patient Network and Advocacy Groups. Orphan drugs: Understanding the rare disease market and its dynamics. Elsevier Ltd; 2013: 101-125
• 10 Anzelewicz S, Garnier H, Rangaswami A, Czauderna P. Cultural, geographical and ethical questions when looking to enroll pediatric patients in rare disease clinical trials. Expert Opin Orphan Drugs 2017; 5 (08) 613-621
• 11 Pritchard-Jones K, Dixon-Woods M, Naafs-Wilstra M, Valsecchi MG. Improving recruitment to clinical trials for cancer in childhood. Lancet Oncol 2008; 9 (04) 392-399
• 12 Pritchard-Jones K. ; SIOP Europe. Clinical trials for children with cancer in Europe - still a long way from harmonisation: a report from SIOP Europe. Eur J Cancer 2008; 44 (15) 2106-2111
• 13 Gatta G, Capocaccia R, Trama A, Martínez-García C. ; RARECARE Working Group. The burden of rare cancers in Europe. Adv Exp Med Biol 2010; 686: 285-303
• 14 Blay JY, Coindre JM, Ducimetière F, Ray-Coquard I. The value of research collaborations and consortia in rare cancers. Lancet Oncol 2016; 17 (02) e62-e69